Tags Result

Sabaa Pharmaceutical turns profitable at EGP 11.9M in H1 2025

Sabaa International for Pharmaceutical and Chemical Industry (SIPC) turned profitable at EGP 11.933 million in the first half (H1) of 2025, compared to net losses valued at EGP 11.443 million in H1 2024

Updated 8/18/2025 11:00:00 AM
Sabaa Pharmaceutical’s losses widen 940.5% in Q1

Sabaa International for Pharmaceutical and Chemical Industry (SIPC) incurred net losses after tax of EGP 1.019 million during the first quarter (Q1) of 2024, up by 940.49% from EGP 98,021 in the year-ago quarter.

Updated 6/2/2024 9:28:00 AM
Sabaa’s profits skyrocket 1,396% YoY in 2023

Sabaa International for Pharmaceutical and Chemical Industry’s (SIPC) net profits after tax soared 1,396.3% year on year (YoY) in 2023 to EGP 271,121, compared to EGP 18,119.

Updated 3/27/2024 10:28:00 AM
Sabaa Pharmaceutical turns to losses in 9 months

Sabaa International for Pharmaceutical and Chemical Industry (SIPC) incurred net losses after tax of EGP 3.881 million during the first nine months of 2023, versus net profits after tax amounting to EGP 488,979 during the same period in 2022.

Updated 11/12/2023 10:55:00 AM
Sabaa Pharmaceutical turns to losses in H1

Sabaa is an Egypt-based company engaged in the pharmaceutical sector. The company’s generic product portfolio includes products focused on different therapeutic categories.

Updated 8/14/2023 9:30:00 AM
Sabaa Pharmaceutical turns to losses in Q1

Sabaa is an Egypt-based company engaged in the pharmaceutical sector. The company’s generic product portfolio includes products focused on different therapeutic categories.

Updated 5/31/2023 11:23:00 AM
Sabaa Pharmaceutical's profit plunge 99.73% in 2022

Saba International is an Egypt-based company operating in the pharmaceutical sector, with a generic product portfolio that includes products focused on different therapeutic categories.

Updated 3/27/2023 11:10:00 AM